Design, synthesis and biological evaluation of indazole–pyrimidine based derivatives as anticancer agents with anti-angiogenic and antiproliferative activities. Issue 5 (29th February 2016)

• Record Type: Journal Article
• Authors: Elsayed, Nevine M. Y.; Abou El Ella, Dalal A.; Serya, Rabah A. T.; Tolba, Mai F.; Shalaby, Raed; Abouzid, Khaled A. M.
• Is Part Of: MedChemComm. Volume 7:Issue 5(2016:May)
• Page Start: 881
• Page End: 899
• Publication Date: 2016-02-29
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c5md00602c
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : Three series of novel indazole–pyrimidine based compounds were designed, synthesized and biologically evaluated as VEGFR-2 kinase inhibitors. Abstract : Three series of novel indazole–pyrimidine based compounds were designed, synthesized and biologically evaluated as VEGFR-2 kinase inhibitors. The most active compound6i (IC50 = 24.5 nM) was further evaluated against a HUVEC cell line showing an IC50 of 1.37 μM. Moreover, it showed an indirect anti-angiogenic effect through the suppression of secretion of VEGF and TGF-b1 from prostate cancer cells. Five compounds were selected by the NCI for evaluation of their in vitro anticancer activity against the full NCI panel of cell lines at 10 μM. Compounds6e and6f were further selected for 5-dose testing. Compound6e exerted nanomolar GI50 values against several cell lines: CCRF-CEM (901 nM), MOLT-4 (525 nM) and CAKI-1 (992 nM) and one digit micromolar activity against the rest of the cell lines ranging from 1.05 μM to 2.41 μM. Compound6f showed one digit micromolar activity against the whole panel of cell lines ranging from 1.55 μM to 7.4 μM. A molecular docking study was employed to investigate the predicted binding mode of the target compounds with VEGFR-2, using Autodock software. Furthermore, MD simulation was implemented for compounds6i and10c for further validation and rationalization of their binding mode.